June 13, 2025 – Talk Bio

AstraZeneca Signs $110M AI-Driven R&D Deal with CSPC Pharmaceutical for Chronic Disease Drugs

2 days ago talkbio0Tagged Aortic Valve Insufficiency, Artificial Intelligence, AstraZeneca, China pharma, Chronic disease, Collaboration, Dosage Forms, Drug Discovery, Drug Industry, GZMH gene, Immune System Diseases, milestone payments, oral therapies

AstraZeneca; CSPC Pharmaceutical; AI drug discovery; chronic diseases; immunological diseases; oral therapies; R&D collaboration; China pharma; milestone payments; pharmaceutical industry

Moderna Wins Expanded FDA Approval for RSV Vaccine in At-Risk Younger Adults

2 days ago talkbio0Tagged Adult, Approved, At-Risk, chronic health conditions, expanded label, Moderna, mRESVIA, RSV vaccine, United States Food and Drug Administration

Moderna; RSV vaccine; FDA approval; mRESVIA; at-risk adults; 18 to 59 years; expanded label; chronic health conditions

J&J CAR-T Therapy Achieves 100% Response Rate in Early-Stage Lymphoma Trial

2 days ago talkbio0Tagged CAR-T therapy, CD19 Antigens, CD20 Antigens, Clinical Trials, dual-targeting, Early-stage, Frequency of Responses, J&J, JNJ-4496, Lymphoma, Phase 1b, relapsed/refractory large-B-cell lymphoma

J&J; CAR-T therapy; lymphoma; early-stage; clinical trial; dual-targeting; CD19; CD20; objective response rate; Phase 1b; JNJ-4496; relapsed/refractory large B-cell lymphoma

Bristol Myers Squibb Hires Goldman Sachs Biotech Analyst Chris Shibutani as Chief Strategy Officer

2 days ago talkbio0Tagged Big Pharma, Chris Shibutani, Corporate, external partnerships, Goldman Sachs, Long-Term Strategy, Myers, squibb

Bristol Myers Squibb; Chris Shibutani; Goldman Sachs; Chief Strategy Officer; long-term strategy; biotech analyst; Big Pharma; external partnerships; corporate strategy

Novo Nordisk Plans Phase 3 Trials for Next-Generation Obesity Drug Amycretin

2 days ago talkbio0Tagged amycretin, Clinical Trials, Glucagon-Like Peptide 1, Nordisk, Obesity, Oral cavity, Phase 3, Receptors, Islet Amyloid Polypeptide, subcutaneous, Weight Loss

Novo Nordisk; amycretin; obesity; clinical trials; Phase 3; GLP-1; amylin receptor; weight loss; subcutaneous; oral

GSK Licenses Experimental Shigella Vaccine to Bharat Biotech for Development and Distribution

2 days ago talkbio0Tagged Bharat, biotech, GMMA platform, low, Microbicides, middle-income countries, Resistance (Psychotherapeutic), Shigella Infections, Shigella Vaccines, SmithKline Beecham, vaccine licensing

GSK; Bharat Biotech; Shigella vaccine; altSonflex1-2-3; vaccine licensing; Shigellosis; GMMA platform; antimicrobial resistance; low and middle-income countries

ADC Therapeutics Cuts 30% of Workforce, Closes UK R&D Site Amid Strategic Shift

2 days ago talkbio0Tagged Antibody-Drug Conjugates, facility closure, layoffs, preclinical programs, R&D, restructuring, Solid Neoplasm, therapeutic autologous dendritic cells, UK, Zynlonta

ADC Therapeutics; layoffs; UK facility closure; biotech restructuring; R&D; antibody-drug conjugates; solid tumors; Zynlonta; preclinical programs